{
    "nct_id": "NCT02905591",
    "official_title": "A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung Cancer",
    "inclusion_criteria": "Note: patients who have a small pleural effusion that is too small to safety tap and is not visible on a chest x-ray are still eligible\n\n* Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) of non-small cell lung cancer.\n* Recommended to receive carboplatin & paclitaxel with radiation therapy as a treatment\n* Tumor or metastatic disease must measure at least 1 cm using a CT scan (CAT scan)\n* Physician determined the patient is healthy enough for chemotherapy and radiation therapy\n* At least part of the lung cancer must be viewable and measurable by CT or MRI\n* A platelet count of at least 100,000 cells per mililiter\n* A creatinine level of less than 1 1/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)\n* Not pregnant, and commit to using birth control during the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Exudative pleural effusion\n* Recurrent non-small cell lung cancer\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Patients actively receiving insulin or patients whose doctors have recommended current insulin use\n* Patients requiring daily finger-stick blood glucose measurements\n* Patients who are on the following drugs and cannot have a substitution or who decline the substitution:\n\n  * warfarin\n  * flecainide\n  * methadone\n  * amphetamines\n  * quinidine\n  * chlorpropamide\n* Prior radiation therapy that would result in a field overlap\n* Enrolled in another therapeutic clinical trial\n* Uncontrolled, intercurrent illness\n* Lactating women\n* HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy\n\nIf all the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure.",
    "miscellaneous_criteria": ""
}